LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment

Stock News

2025/09/12

LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.

The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1188794473"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188794473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188794473?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188794473","market":"sh","top_or_hot":-1,"title":"LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment","media":"Stock News","content":"<p>LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.</p>\n<p>The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-12 12:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.</p>\n<p>The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1188794473","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188794473","pubTimestamp":1757651064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B","BK1161":"生物科技"},"translate_title":"LEADS BIOLABS-B（09887）：LBL-024治疗黑色素瘤的Ib/II期试验中首位成功给药的患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.\nThe Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}